Novan, Inc. (NOVN)
| Market Cap | 60.87M |
| Revenue (ttm) | 9.48M |
| Net Income (ttm) | -36.98M |
| Shares Out | 21.28M |
| EPS (ttm) | -1.89 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 131,227 |
| Open | 2.90 |
| Previous Close | 2.92 |
| Day's Range | 2.84 - 2.99 |
| 52-Week Range | 2.15 - 10.40 |
| Beta | 0.34 |
| Analysts | Buy |
| Price Target | 19.89 (+595.5%) |
| Earnings Date | Aug 11, 2022 |
About NOVN
Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the tr... [Read more...]
Financial Performance
In 2021, Novan's revenue was $2.96 million, a decrease of -39.88% compared to the previous year's $4.92 million. Losses were -$29.69 million, 1.36% more than in 2020.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for NOVN stock is "Buy." The 12-month stock price forecast is 19.89, which is an increase of 595.45% from the latest price.
News
Novan Reports Second Quarter 2022 Financial Results and Provides Corporate Update
– Total revenue of $6.2 million for the second quarter 2022 –
Novan to Report Second Quarter 2022 Financial Results on August 11, 2022
DURHAM, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its second quarter 2022 financial results on Thursday, August 1...
Novan Satisfies $16.5 Million Outstanding Promissory Note
– Novan and Evening Post Group enter into a loan payoff and termination agreement, fully satisfying the promissory note and all related obligations –
Novan Announces Closing of Approximately $15.0 Million Registered Direct Offering Priced At-the-Market
DURHAM, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the closing of the Company's previously announced registered direct offering priced...
Novan Announces Approximately $15.0 Million Registered Direct Offering Priced At-the-Market
DURHAM, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it has entered into a definitive agreement with an institutional investor to sell t...
Novan to Present Berdazimer Gel, 10.3% (SB206) Clinical Data at Annual Meeting of the Society for Investigative Derma...
– Based on clinical data from previously completed B-SIMPLE4 pivotal Phase 3 clinical study, berdazimer gel, 10.3% (SB206) can shorten the duration of molluscum infection and increase the chance of clea...
Novan Reports First Quarter 2022 Financial Results and Provides Corporate Update
– Transformational quarter for Novan, marked by acquisition of EPI Health –
Novan to Report First Quarter 2022 Financial Results on May 16, 2022
DURHAM, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2022 financial results on Monday, May 16th. No...
Novan to Participate in the Virtual Investor Innovation in Dermatology Spotlight Event
Live moderated video webcast with members of the Novan management team on Tuesday, April 26th at 2:00 PM ET Live moderated video webcast with members of the Novan management team on Tuesday, April 26th ...
Novan Announces Late-Breaking Abstract Accepted for Presentation at American Academy of Dermatology's (AAD) 2022 Annu...
DURHAM, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from its pivotal Phase 3 study of berdazimer gel 10.3% (SB206) for the t...
Novan, Inc. to Present at Two Upcoming Investor Conferences
DURHAM, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will be...
EVENING POST GROUP SELLS EPI HEALTH TO NOVAN, INC
CHARLESTON, S.C., March 11, 2022 /PRNewswire/ -- Evening Post Group ("EPG"), a family-owned operating group based in Charleston, South Carolina, is excited to announce the successful sale of EPI Health,...
Novan Acquires EPI Health To Bolster Commercial Force For Potential Marketing Of Its lead Products
Novan Inc (NASDAQ: NOVN) has acquired EPI Health LLC, a specialty pharmaceutical company focused on the U.S. dermatology market. EPI Health offers a product portfolio that includes four prescription pr...
Novan Acquires EPI Health, a Specialty Dermatology Company
Acquisition Represents Forward Integration as a Commercial Organization Acquisition Represents Forward Integration as a Commercial Organization
Novan Reports Full Year 2021 Financial Results and Provides Corporate Update
– First New Drug Application (NDA) submission targeted in Q4 2022 for lead program SB206 (berdazimer gel 10.3%) for molluscum contagiosum –
Novan to Report Full Year 2021 Financial Results on February 22, 2022
DURHAM, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2021 financial results on Tuesday, February 22nd....
Novan Announces Presentation of Two Posters at the 2022 Winter Clinical Dermatology Conference
DURHAM, N.C., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from the Company's completed Phase 2 and Phase 3 clinical studies of berd...
Novan to Participate in the Virtual Investor Roundtable Event
– Live moderated video webcast discussion among management and Pediatric Dermatology Thought Leader on Wednesday, November 17 th at 1:00 PM ET –
Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results
– Company executing on plans for three potential New Drug Application (NDA) filings in three years with the first submission targeted in Q3 2022 for lead program SB206 in molluscum contagiosum –
Novan Announces Favorable Preclinical Safety Data and Intent to Advance SB019 for Treatment of COVID-19
– Data indicate that intranasal administration of SB019 formulation containing berdazimer sodium is well-tolerated and safe under the conditions of preclinical study –
Novan Announces Fireside Chat Hosted by Jonathan Aschoff, Ph.D. of ROTH Capital Partners
– Company highlights rationale of strategic pathway towards potential commercialization in collaboration with commercial solutions provider, Syneos Health –
Novan to Report Third Quarter 2021 Financial Results on November 10, 2021
Company to host conference call and webcast on Wednesday, November 10, 2021, at 8:30 a.m. ET Company to host conference call and webcast on Wednesday, November 10, 2021, at 8:30 a.m. ET
Novan Appoints Brian M. Johnson as Chief Commercial Officer and Receives Conditional FDA Acceptance of Proposed Brand...
– Mr. Johnson brings broad commercial expertise with over 30 years of leadership spanning dermatology marketing, sales, sales management, digital marketing and managed care – – Company received conditio...
Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206
– SB206 demonstrates continued favorable safety profile consistent with previous studies and meets Company's expectations –
Novan to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
– Live fireside chat with Paula Brown Stafford, President and Chief Executive Officer of Novan on Tuesday, September 28 at 8:00 AM ET – – Live fireside chat with Paula Brown Stafford, President and Chie...